Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment

mutation ( m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Ca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Future oncology (London, England) England), 2023-03, Vol.19 (8), p.559-573
Hauptverfasser:	Turner, Nicholas, Huang-Bartlett, Cynthia, Kalinsky, Kevin, Cristofanilli, Massimo, Bianchini, Giampaolo, Chia, Stephen, Iwata, Hiroji, Janni, Wolfgang, Ma, Cynthia X, Mayer, Erica L, Park, Yeon Hee, Fox, Steven, Liu, Xiaochun, McClain, Sasha, Bidard, Francois-Clement
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Aromatase Inhibitors - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Clinical Trials, Phase III as Topic Female Fulvestrant - therapeutic use Humans Life Sciences Randomized Controlled Trials as Topic Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!